Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Otolaryngol Clin North Am. 2017 Sep 28;50(6):1135–1151. doi: 10.1016/j.otc.2017.08.009

Table 2.

Studies of other biologics or small molecules targeting type 2 pathways studied in humans

Other agents with prospective applications
Study Year Drug name & Mechanism Study population End points Interesting points or problem with study
Arm JP, Bottoli I et al. 2014 ligelizumab - Anti IgE Atopic patients serum IgE levels
NCT01362244 Ongoing Mepolizumab - Anti-IL-5 105 CRSwNP patients refractory to conventional therapy Time to surgery or polyp recurrence after salvage therapy Will effectively assess duration of action
NCT02772419 Ongoing Benralizumab - Anti IL5 Receptor Eosinophilic CRS patients
NCT02734849 Ongoing AK001 - Anti-Siglec-8 CRSwNP Phase 2 RCT
NCT02170337 Ongoing AMG282 - Anti-IL33/ST2 receptor 41 CRSwNP patients and healthy volunteers

  1. Safety

  2. pharmacokinetics

 Phase 1 RCT
AMG 157 - Anti TSLP only studied in asthmatic and Atopic dermatitis patients
Small molecule inhibitors of the Type 2 pathway
SB010 - GATA3 DNAzyme only studied in asthmatic patients
NCT02874144 OC000459 - CRTH2 antagonist AR and asthmatic patients
Dexpramipexole Eosinophil associated diseases, CRS Absolute eosinophil levels